Cargando…
Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial
BACKGROUND: The FOCUS study evaluated the efficacy of migraine preventive medications across different countries within the same patient population, particularly for patients with difficult-to-treat migraine. These prespecified subgroup analyses evaluated efficacy by country in the FOCUS study of fr...
Autores principales: | Spierings, Egilius L. H., Kärppä, Mikko, Ning, Xiaoping, Cohen, Joshua M., Campos, Verena Ramirez, Yang, Ronghua, Reuter, Uwe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052719/ https://www.ncbi.nlm.nih.gov/pubmed/33863272 http://dx.doi.org/10.1186/s10194-021-01232-8 |
Ejemplares similares
-
Fremanezumab for the Preventive Treatment of Migraine: Subgroup
Analysis by Number of Prior Preventive Treatments with Inadequate
Response
por: Pazdera, Ladislav, et al.
Publicado: (2021) -
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine‐preventive medications in the phase 3b FOCUS study
por: Spierings, Egilius L. H., et al.
Publicado: (2021) -
Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study
por: MaassenVanDenBrink, Antoinette, et al.
Publicado: (2021) -
The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study
por: Silberstein, Stephen D., et al.
Publicado: (2020) -
Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid
por: Ferrari, Michel D., et al.
Publicado: (2022)